Amicus Therapeutics Inc
(LTS:0HF9)
$
10.0592
0.0812 (0.81%)
Market Cap: 2.98 Bil
Enterprise Value: 3.17 Bil
PE Ratio: 0
PB Ratio: 16.66
GF Score: 81/100 Amicus Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022 / 04:20PM GMT
Release Date Price:
$11.09
Andrew Francis Galler
Morgan Stanley, Research Division - Equity Analyst
All right. Good afternoon, everyone. I'm Andrew Geller, one of the biotech analysts here at Morgan Stanley, and I'm pleased to be joined by Brad Campbell, President and CEO of Amicus Therapeutics.
Brad, thanks for joining us today.
Bradley L. Campbell
Amicus Therapeutics, Inc. - CEO, President & Director
Yes. Thanks, Andrew. Thanks to Morgan Stanley for hosting us today. And a great...
Andrew Francis Galler
Morgan Stanley, Research Division - Equity Analyst
Just before we start, I have to read some disclosure statements.
Bradley L. Campbell
Amicus Therapeutics, Inc. - CEO, President & Director
Please go ahead.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot